Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0829 has been discontinued.
View all Non-selective Adrenergic β Receptors products.Pronethalol hydrochloride is an β-adrenergic antagonist, clinically effective in the treatment of angina pectoris and some arrhythmias.
Sold with the permission of AstraZeneca UK Ltd.
分子量 | 265.78 |
公式 | C15H19NO.HCl |
储存 | Store at RT |
纯度 | ≥99% (HPLC) |
CAS Number | 51-02-5 |
PubChem ID | 60975 |
InChI Key | QONLGXRPRAIDGI-UHFFFAOYSA-N |
Smiles | Cl.CC(C)NCC(O)C1=CC=C2C=CC=CC2=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Main (1990) α-Adrenergic receptors. Comprehensive Medicinal Chemistry. Ed Hansch 3 187
Merck Index 12 7974
关键词: Pronethalol hydrochloride, Pronethalol hydrochloride supplier, β-adrenoceptor, beta-adrenoceptors, β-adrenergic, beta-adrenergic, b-adrenoceptors, b-adrenergic, antagonists, Receptors, Non-Selective, ICI38174, AstraZeneca, ICI-38174, Non-selective, Adrenergic, Beta, 0829, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 Pronethalol hydrochloride 的部分引用包括:
Kaya et al (2009) Coupling of β2-adrenoceptors to XLαs and Gαs: a new insight into ligand-induced G protein activation. J Pharmacol Exp Ther 329 350 PMID: 19144685
目前没有该产品的评论。 Be the first to review Pronethalol hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.